DE69736712D1 - Verfahren zur milderung von neuropatischen schmerz mit prosaposin verwandten peptiden - Google Patents

Verfahren zur milderung von neuropatischen schmerz mit prosaposin verwandten peptiden

Info

Publication number
DE69736712D1
DE69736712D1 DE69736712T DE69736712T DE69736712D1 DE 69736712 D1 DE69736712 D1 DE 69736712D1 DE 69736712 T DE69736712 T DE 69736712T DE 69736712 T DE69736712 T DE 69736712T DE 69736712 D1 DE69736712 D1 DE 69736712D1
Authority
DE
Germany
Prior art keywords
prosaposin
neuropathic pain
reducing neuropathic
subject
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69736712T
Other languages
English (en)
Other versions
DE69736712T2 (de
Inventor
S O'brien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of DE69736712D1 publication Critical patent/DE69736712D1/de
Publication of DE69736712T2 publication Critical patent/DE69736712T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DE69736712T 1996-03-05 1997-03-05 Verfahren zur milderung von neuropatischen schmerz mit prosaposin verwandten peptiden Expired - Fee Related DE69736712T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US611307 1996-03-05
US08/611,307 US6271196B1 (en) 1996-03-05 1996-03-05 Methods of alleviating neuropathic pain using prosaposin-derived peptides
PCT/US1997/004143 WO1997032895A1 (en) 1996-03-05 1997-03-05 Methods of alleviating neuropathic pain using prosaposin-derived peptides

Publications (2)

Publication Number Publication Date
DE69736712D1 true DE69736712D1 (de) 2006-11-02
DE69736712T2 DE69736712T2 (de) 2007-09-13

Family

ID=24448513

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69736712T Expired - Fee Related DE69736712T2 (de) 1996-03-05 1997-03-05 Verfahren zur milderung von neuropatischen schmerz mit prosaposin verwandten peptiden

Country Status (16)

Country Link
US (2) US6271196B1 (de)
EP (1) EP0929569B1 (de)
JP (1) JP4138006B2 (de)
KR (1) KR100507715B1 (de)
AT (1) ATE340187T1 (de)
AU (1) AU734566B2 (de)
CA (1) CA2248139C (de)
CZ (1) CZ297384B6 (de)
DE (1) DE69736712T2 (de)
IL (1) IL126082A0 (de)
NO (1) NO984093L (de)
NZ (1) NZ331757A (de)
PL (1) PL187917B1 (de)
RU (2) RU2266129C2 (de)
SK (1) SK122898A3 (de)
WO (1) WO1997032895A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) * 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US6849602B1 (en) * 1996-03-05 2005-02-01 The Regents Of The University Of California Compositions for alleviating neuropathic pain with prosaposin receptor agonists
WO1998039357A1 (en) * 1997-03-05 1998-09-11 The Regents Of The University Of California Method of alleviating neuropathic pain
AU4267297A (en) * 1997-09-11 1998-09-22 Regents Of The University Of California, The Method of alleviating neuropathic pain
EP0971956A2 (de) * 1997-03-24 2000-01-19 Myelos Corporation Von saposin c abgeleitete neurotrophe peptide
CA2304108A1 (en) * 1997-09-09 1999-03-18 The Regents Of The University Of California Inhibition of apoptotis using prosaposin receptor agonists
US6458357B1 (en) * 1997-09-09 2002-10-01 Myelos Corporation Retro-inverso neurotrophic and analgesic peptides
EP1105420A1 (de) * 1998-08-28 2001-06-13 Myelos Corporation Zyklische von prosaposin abgeleitete peptide und deren verwendung
US20020028783A1 (en) * 1999-09-09 2002-03-07 O'brien John S. Method of stimulating prosaposin receptor activity
USRE45976E1 (en) * 1999-02-24 2016-04-19 Tact Ip, Llc Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally
AU4328500A (en) * 1999-03-30 2000-10-16 Myelos Corporation Retro-inverso prosaposin-derived peptides and use thereof
US7410941B1 (en) 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
JP4786843B2 (ja) * 1999-06-16 2011-10-05 マイアロス コーポレイション インターロイキン−６から誘導されるレトロ−インベルソペプチド
CA2376474A1 (en) * 1999-06-16 2000-12-21 David E. Wright Retro-inverso peptides derived from leukemia inhibitory factor
US7135461B1 (en) 2000-06-16 2006-11-14 Myelos Corporation Retro-inverso peptides derived from interleukin-6
US7109168B1 (en) 2000-06-16 2006-09-19 Myelos Corporation Retro-inverso peptides derived from leukemia inhibitory factor
WO2000077028A1 (en) * 1999-06-16 2000-12-21 Myelos Corporation Retro-inverso peptides derived from interleukin-3
US20040170955A1 (en) * 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US20050074747A1 (en) * 2000-09-08 2005-04-07 Wadih Arap Biopanning and rapid analysis of selective interactive ligands (brasil)
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20060287240A1 (en) * 2001-03-09 2006-12-21 O'brien John S Method of stimulating prosaposin receptor activity
WO2003007979A1 (en) * 2001-07-18 2003-01-30 Board Of Regents, The University Of Texas System An anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration
US8507445B2 (en) * 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20040048243A1 (en) * 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
AU2003259846A1 (en) * 2002-08-16 2004-03-03 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
US7166691B2 (en) * 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
EP1605965B1 (de) * 2003-03-26 2012-12-26 DeveloGen Aktiengesellschaft Verwendung von mit saposin verwandten proteinen zur prävention und behandlung von adipositas, diabetes und/oder des metabolischen syndroms
KR20050112116A (ko) * 2003-03-28 2005-11-29 아카디아 파마슈티칼스 인코포레이티드 통증 관리를 위한 무스카린성 ｍ1 리셉터 작용제
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
CN100366286C (zh) * 2003-04-28 2008-02-06 常州南云科技有限公司 Saposin C-DOPS:一种抗癌新药
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US7964585B2 (en) * 2006-03-14 2011-06-21 Case Western Reserve University Composition and method of treating peripheral neuropathy
SG188161A1 (en) 2008-01-22 2013-03-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
RU2561582C2 (ru) * 2010-11-19 2015-08-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Инъекционная лекарственная форма олигопептидного препарата для лечения рассеянного склероза и способ ее получения
WO2012115185A1 (ja) * 2011-02-23 2012-08-30 北海道公立大学法人札幌医科大学 疼痛を治療、改善、または予防するための組成物
RU2669692C1 (ru) * 2017-08-14 2018-10-15 Павел Андреевич Канаев Способ получения комплекса биологически активных пептидов обладающих нейротропной активностью
KR102370952B1 (ko) * 2018-03-23 2022-03-07 벡션 파마슈티컬스 인크. 사포신 c 약학 조성물 및 암 치료 방법
CA3093594A1 (en) 2018-03-29 2019-10-03 Lateral IP Pty Ltd Cyclic peptides and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0246753B1 (de) 1986-04-22 1994-07-13 The Salk Institute For Biological Studies Antagonisten des Fibroblasten-Wachstumsfaktors
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
WO1998039357A1 (en) * 1997-03-05 1998-09-11 The Regents Of The University Of California Method of alleviating neuropathic pain
EP0971956A2 (de) * 1997-03-24 2000-01-19 Myelos Corporation Von saposin c abgeleitete neurotrophe peptide

Also Published As

Publication number Publication date
US6268347B1 (en) 2001-07-31
RU2223969C2 (ru) 2004-02-20
AU2328697A (en) 1997-09-22
IL126082A0 (en) 1999-05-09
RU2003131695A (ru) 2005-04-10
CA2248139A1 (en) 1997-09-12
ATE340187T1 (de) 2006-10-15
SK122898A3 (en) 2000-02-14
RU2266129C2 (ru) 2005-12-20
EP0929569B1 (de) 2006-09-20
EP0929569A4 (de) 2000-08-23
WO1997032895A1 (en) 1997-09-12
AU734566B2 (en) 2001-06-14
DE69736712T2 (de) 2007-09-13
JP4138006B2 (ja) 2008-08-20
JP2000506853A (ja) 2000-06-06
CA2248139C (en) 2004-05-18
CZ297384B6 (cs) 2006-11-15
KR19990087686A (ko) 1999-12-27
EP0929569A1 (de) 1999-07-21
NO984093L (no) 1998-11-04
PL328701A1 (en) 1999-02-15
US6271196B1 (en) 2001-08-07
CZ283998A3 (cs) 1999-05-12
NO984093D0 (no) 1998-09-04
PL187917B1 (pl) 2004-11-30
NZ331757A (en) 1999-10-28
KR100507715B1 (ko) 2006-05-26

Similar Documents

Publication Publication Date Title
DE69736712D1 (de) Verfahren zur milderung von neuropatischen schmerz mit prosaposin verwandten peptiden
ATE338563T1 (de) Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus- interferon
DE69427869D1 (de) Botulinumtoxine zur behandlung von hyperhydrosis
AU2987695A (en) Interruption of binding of mdm2 and p53 protein and therapeutic application thereof
TJ392B (en) Fraction of copolymer-1 and method prodaction of it, composition for the treatment of multiple sclerosis, farmaceutical composition, method for the t reatment of multiple sclerosis.
SG50624A1 (en) Methods of producing analgesia and enhancing opiate analgesia
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
SE9603068D0 (sv) Process for purifying a protein
ATE342278T1 (de) Verfahren zur behandlung von diabetes mittels kgf
DE69533704D1 (de) Bradykinin-antagonist peptide mit n-substituierten glycinen
ZA962566B (en) Control of pod dehiscence.
ZA947783B (en) Method of treating depressed reticuloendothelial system function
DE69626311T2 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
EA199800866A1 (ru) Способ снятия боли
ATE381577T1 (de) Verfahren zur aufreinigung von apolipoprotein-a oder apolipoprotein-e aus menschlichem plasma
DE69837265D1 (de) Polypeptide zur regenerierung des nervensystems
DE59607379D1 (de) Verfahren zur destillation von ethylenoxid
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
IL126158A0 (en) Method for treating substance abuse
PL328949A1 (en) Method of treatng excessive aggression
HUP9902550A2 (hu) Eljárások neuropátiás fájdalom prosaposinszármazék peptidekkel történő enyhítésére
EA199800818A1 (ru) Способ лечения бессонницы
UA43389C2 (uk) Спосіб зниження рівнів кальцію у сироватці

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee